Acutaas Chemicals Reports Increased Q2 FY25 EPS Despite Lower Total Income
Acutaas Chemicals announced Q2 and half-year FY25 unaudited financial results, showing basic EPS increased to ₹8.84 (standalone) and ₹8.90 (consolidated) for the quarter, despite a decrease in total income.
Although earnings per share showed a strong increase, the total income for both standalone and consolidated results for the quarter and half-year decreased compared to the previous year, indicating mixed financial performance.
The company reported a significant increase in basic earnings per share for the second quarter ended September 30, 2025, for both standalone (₹8.84 vs. ₹5.45) and consolidated (₹8.90 vs. ₹5.45) results compared to the previous year's corresponding quarter.
Acutaas Chemicals Limited (formerly Ami Organics Limited) has published its Standalone and Consolidated Unaudited Financial Results for the second quarter and half year ended September 30, 2025. The publication appeared on Saturday, October 18, 2025, in the Financial Express (All India English and Ahmedabad Gujarati editions), in compliance with SEBI Regulations 30 & 47. The Audit Committee reviewed and the Board of Directors approved these results at a meeting held on October 17, 2025.
Key financial highlights for the second quarter ended September 30, 2025: * Total Income (Standalone): ₹6,00.18 lakhs, down from ₹7,14.50 lakhs in Q2 FY24. * Total Income (Consolidated): ₹6,23.16 lakhs, down from ₹7,18.59 lakhs in Q2 FY24. * Basic Earnings per Share (Standalone, ₹5 each): ₹8.84, significantly up from ₹5.45 in Q2 FY24. * Basic Earnings per Share (Consolidated, ₹5 each): ₹8.90, significantly up from ₹5.45 in Q2 FY24.
Key financial highlights for the half year ended September 30, 2025: * Total Income (Standalone): ₹11,85.67 lakhs, down from ₹14,23.36 lakhs in H1 FY24. * Total Income (Consolidated): ₹12,19.25 lakhs, down from ₹14,57.58 lakhs in H1 FY24.
The detailed financial results are available on the websites of BSE, NSE, and the company's website.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.